key: cord-0816389-ts87u9ou
authors: van Dam, L.F.; Kroft, L.J.M.; van der Wal, L.I.; Cannegieter, S.C.; Eikenboom, J.; de Jonge, E.; Huisman, M.V.; Klok, F.A.
title: Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?
date: 2020-06-06
journal: Thromb Res
DOI: 10.1016/j.thromres.2020.06.010
sha: a9c8c00fee3d6865f6df8269d5fd174e89707722
doc_id: 816389
cord_uid: ts87u9ou

INTRODUCTION: COVID-19 infections are associated with a high prevalence of venous thromboembolism, particularly pulmonary embolism (PE). It is suggested that COVID-19 associated PE represents in situ immunothrombosis rather than venous thromboembolism, although the origin of thrombotic lesions in COVID-19 patients remains largely unknown. METHODS: In this study, we assessed the clinical and computed tomography (CT) characteristics of PE in 23 consecutive patients with COVID-19 pneumonia and compared these to those of 100 consecutive control patients diagnosed with acute PE before the COVID-19 outbreak. Specifically, RV/LV diameter ratio, pulmonary artery trunk diameter and total thrombus load (according to Qanadli) were measured and compared. RESULTS: We observed that all thrombotic lesions in COVID-19 patients were found to be in lung parenchyma affected by COVID-19. Also, the thrombus load was lower in COVID-19 patients (Qanadli score −8%, 95% confidence interval [95%CI] −16 to −0.36%) as was the prevalence of the most proximal PE in the main/lobar pulmonary artery (17% versus 47%; −30%, 95%CI −44% to −8.2). Moreover, the mean RV/LV ratio (mean difference −0.23, 95%CI −0.39 to −0.07) and the prevalence of RV/LV ratio >1.0 (prevalence difference −23%, 95%CI −41 to −0.86%) were lower in the COVID-19 patients. CONCLUSION: Our findings therefore suggest that the phenotype of COVID-19 associated PE indeed differs from PE in patients without COVID-19, fuelling the discussion on its pathophysiology.

COVID-19 infections are associated with frequent activation of the coagulation system. This so-called COVID-19 coagulopathy has been shown to be predictive of poor outcome and excess mortality. (1) (2) (3) (4) (5) (6) Moreover, COVID-19 illness is associated with high rates of venous thromboembolism, particularly acute pulmonary embolism (PE).(7-14) This high rate of venous thromboembolic complications is likely related to the COVID-19 coagulopathy, in combination with well-known strong thrombotic risk factors including inflammation, hypoxia and immobilisation, which all become more pronounced in critically ill patients. Based on autopsy studies, it has been proposed that the inflammatory process in the microcirculation of the lung may cause in situ immunothrombosis. (15, 16) This suggests an alternative explanation to the conventional thromboembolic pathomechanism of PE. (17) To investigate this hypothesis, we set out to determine the clinical and computed tomography (CT) characteristics of acute PE in COVID-19 patients, and compare these to the characteristics of acute PE in patients without COVID-19 pneumonia.

We included all adult patients admitted to the Leiden University Medical Center (LUMC) with polymerase chain reaction (PCR) proven COVID-19 infection and computed tomography pulmonary angiography (CTPA) proven acute PE between March 19 th and April 14 th . Additionally, we studied a convenience control cohort, in whom all radiological parameters had been assessed as part of an ongoing observational study. This control group consisted of 100 consecutive adult patients with J o u r n a l P r e -p r o o f CT characteristics of COVID-19 associated acute PE 4 ordered without prior clinical probability scoring and/or D-dimer testing. This study was approved by the Institutional Review Board of the LUMC for observational studies.

We aimed to determine the clinical and CT parameters of patients with COVID-19 associated PE, i.e. the reasons for clinical suspicion of PE, the location of the pulmonary emboli in the pulmonary artery tree in general and in relation to COVID-19 affected pulmonary segments, total thrombus load, right to left ventricular diameter ratio (RV/LV ratio) and pulmonary artery trunk diameter. We compared the CT characteristics of acute PE in COVID-19 patients to those assessed in the control cohort.

CTPA examinations were performed on a 320-multislice detector row CT scanner (Canon) after iodinated contrast administration. RV/LV ratio, pulmonary artery trunk diameter and total thrombus load for both COVID-19 cases and controls were evaluated by an expert thoracic radiologist (LK) with over 20 years of experience in CTPA reading. The maximum diameters of both the RV and LV were measured in the standard axial view in which the maximal distance between the ventricular endocardium and the interventricular septum perpendicular to the long axis of the heart were assessed. The pulmonary artery trunk was measured at its largest transverse diameter. The thrombus load was assessed by using the Qanadli CT pulmonary artery obstruction index, including 10 lung segments for each lung. (19) For each PE location, ground glass opacities or consolidations were reported as being present or not present for each affected lung segment. Also, the extent of COVID-19 lung lesions by ground-glass opacities and consolidations was visually assessed as percentage of affected lung volume.

Clinical and CT characteristics of PE are described as mean with standard deviation (SD) or median with interquartile range (IQR). We calculated absolute differences in these characteristics between COVID-19 patients and controls with corresponding 95% confidence interval (95%CI). All statistical analyses were performed in SPSS version 25 (IBM, Armonk, NY, USA).

A total of 23 patients with proven COVID-19 pneumonia and symptomatic CTPA proven PE were included in the study. Their baseline characteristics are shown in Table 1 . All received pharmacological thromboprophylaxis. The main reason for PE suspicion was lack of clinical improvement in ventilated patients (n=13, 57%), sudden unexpected respiratory deterioration (n=7, 30%), hemodynamic collapse (n=2, 8.7%) and persistent fever of unknown origin (n=1, 4.3%).

In the COVID-19 cohort, the most proximal PE was located in the main/lobar pulmonary artery in 4 (17%) patients, and the most proximal PE was in a segmental artery in 16 (70%) (Figure 1) .

In 3 patients (13%), the PE was limited to subsegmental arteries and 1 patient had a single subsegmental PE (4.3%). The mean total Qanadli score was 23% (SD 18%). Overall, 426/460 (93%) of the anatomical lung segments in the 23 patients were affected by COVID-19 and the mean percentage of affected lung was 58% (SD 22%). A total of 178/460 (39%) pulmonary artery segments were affected by PE; all pulmonary artery segments with PE were in lung parenchyma with radiological signs of COVID-19 pneumonia. The mean RV/LV ratio was 0.97 (SD 0.15) and the mean pulmonary trunk diameter was 29mm (SD 4.6mm). Six patients had a RV/LV ratio >1.0 (26%).

The control cohort consisted of 100 patients ( Table 1 ). The location of the most proximal PE in the COVID-19 patients was less often the main/lobar pulmonary artery than in the control patients (17% versus 47%; -30%, 95%CI -44 to -8.2%). The Qanadli score was lower in the COVID-19 patients (mean difference -8%, 95%CI -16 to -0.13) as was the mean RV/LV ratio (mean difference -0.23, 95%CI -0.39 to -0.07) and the prevalence of RV/LV ratio >1.0 (26% versus 49%; -23%, 95%CI -41 to -0.86%). The mean pulmonary trunk diameter was comparable between cases and controls.

J o u r n a l P r e -p r o o f

Our findings suggest that the PE phenotype in patients with COVID-19 is different from PE patients without COVID-19 pneumonia. Specifically, in COVID-19 patients, the thrombotic lesions were more distributed in the peripheral arteries of the lung, total clot burden was lower and the mean RV/LV ratio and prevalence of RV/LV ratio > 1 were lower.

Differences between patients with COVID-19 associated PE and the control patients related to thrombosis risk (e.g. sex or BMI) may explain our observations. The relatively small sample size did not allow performing multivariate analyses to adjust for these differences. Nevertheless, sex and BMI have been shown not to be associated with clot burden or distribution in previous studies so we feel this explanation is less likely. (17) Active malignancy -n (%) 1 (4) 27 (27) Trauma/surgery during the past 4 weeks -n (%) 0 (0) 22 (22) Clinical presentation 

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine

Vander Heide RS. Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans

Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study

New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography

Diagnostic implications of computed tomography pulmonary angiography in patients with pulmonary embolism

Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Acute Pulmonary Embolism and COVID-19

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum

Note: *Only for non-sedated non-intubated patients

None

FAK, LJMK and LFvD designed the study and gathered data. They performed the analyses and drafted the first version of the manuscript. All authors revised the manuscript critically for important intellectual content and agreed with the final version.